



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

**Public Summary**

<b>Summary for ARTG Entry:</b>	237276	ageLOC Y-Span
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Nu Skin Enterprises Australia Inc	
<b>Postal Address</b>	PO Box 116, NORTH RYDE BC, NSW, 1670 Australia	
<b>ARTG Start Date</b>	7/05/2015	
<b>Product category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval area</b>	Listed Medicines	

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

**Products**

**1. ageLOC Y-Span**

<b>Product Type</b>	Single Medicine Product	<b>Effective date</b>	23/06/2015
---------------------	-------------------------	-----------------------	------------

**Permitted Indications**

No Permitted Indications included on Record

**Indication Requirements**

No Indication Requirements included on Record

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

- ageLOC Y-Span is based upon gene expression science
- ageLOC Y-Span may help support cellular protection and repair/the body's protection and repair mechanisms at the cellular level/healthy cellular response
- ageLOC Y-Span may help to preserve cognition and memory in older people
- ageLOC Y-Span supports healthy lipid metabolism
- ageLOC Y-Span helps support overall cardiovascular health
- ageLOC Y-Span is our most advanced supplement inspired by scientific research of healthy aging

**Warnings**

- Do not take while on warfarin therapy without medical advice.
- Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

**Additional Product information**

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1. Formulation 1**

**Dosage Form**

Capsule, hard

**Route of Administration**

Oral

**Visual Identification**

**Active Ingredients**

alpha lipoic acid	25 mg
Citrus bioflavonoids extract	76.95 mg
colecalfiferol	50 IU
concentrated fish Omega-3 triglycerides	527.5 mg
lutein	1.25 mg
Lycopene	1.25 mg
Orange Oil	13.16 mg
Quercetin	18.75 mg
Rosemary Oil	2.344 mg
ubidecarenone	7.25 mg
Zea mays	33.33 mg
Equivalent: Zea mays (Dry)	1.133 g

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary